The addition of Lynparza to presurgical chemotherapy did not improve outcomes for patients with basal-like BRCA wild-type triple-negative breast cancer.
Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.